[email protected]
Understand the COVID-19 Outbreak and its impact on global & regional businesses
request free proposal
Insights on a world turned upside down : Re-imagining
The post-COVID19 Business resilience & recovery
How effective strategies and business recovery plans are winning the race
request free proposal
Goldstein Market Intelligence help you navigate through the COVID-19 crisis,
we will provide you most relevant market insights on crisis management,
recovery strategy & business continuity.
2020-03-23
736
Global
“Unvaccinatable” targets like HIV and hepatitis C were in the bull’s-eye, for the very first time and traditional vaccine technology (live or inactivated viruses), was unable to provide a viable way to provoke a protective immune response against these diseases. However, considerable amount of potential vaccines in the pipeline tends to change the dynamics of the pharmaceutical business in the future.
By Target Areas
Trends: New vaccine development from the combination of new science (genomics and proteomics), new approaches (DNA vaccines, new combination vaccines, new formulations, novel delivery routes, new adjuvants) and new needs (defence vaccines) for potential use in human medicine is buoyant. In addition, our report covers: DNA Vaccination, Recent Project Terminations, Innovative Delivery Systems, Edible Vaccines, Vaccine Patches, Funding Shortfalls.
Challenges: Viral vectors used for vaccine production are genetically modified organisms (GMOs) and are therefore considered a potential risks to human health and environment associated with the release of these organisms. In order to track the vaccine based projects, European regulatory agencies require environmental risks assessment (ERA) and in USA, the FDA has published guidelines for Environmental Assessments (EA)to evaluate potential environmental and health risks posed by the GMO.
Drivers: Thinking out of syringe idea has emerged with oral form of the rotavirus vaccine, edible vaccines, mucosally delivered vaccines, intranasal vaccines, patch vaccines and vaccine chips are also all under development for other viruses is driving the global next generation market.
HIV vaccine research makes up more than half of all R&D spending on the disease: USD 652 million, or 60 %, in 2014. Malaria vaccine research received a large bump in 2014, increasing its share of R&D funding from USD 120 million to USD 173 million, following several years of declining investment.Several vaccine candidates in clinical development are still at phase II stage, targeting infants and young children, or as potential boosters for the BCG vaccine. Along with HIV and malaria, TB vaccine research has also suffered consecutive declines in funding since the beginning of the decade.
Solution: Sustainable and sufficient funding, coherent investment strategy and support for innovation across the development cycle.
Our Global Next Generation Vaccine Market report comprises of the following companies as the key players
For a full detailed overview, send here request for market report sample.
A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements
OR Call Us:+1-646-568-7747Global Injectable Drugs Market Report: Market Segmentation Based on Product Type & by Region with Forecast 2017-2030
Global Dengue Vaccine Market Outlook 2024: Global Opportunity and Demand Analysis, Market Forecast, 2016-2024
Global Malaria Vaccine Market Report by Product, by Distribution Channel, by Gender, & by Region with Forecast 2017-2030
Global Vaccine Market Analysis By Group (Adult & Paediatric Vaccines) & By Type (Live Attenuated, Inactivated Vaccines, Subunit Vaccines & Next Generation Vaccines ) with Regional Outlook & Forecast to 2025
Global Pediatric Vaccines Market Analysis by Technology, by Vaccine Type & by End User with Regional Outlook & Forecast to 2025